Next-Generation Hypertension Management: Therapies, Devices, and Decision-Making

Description

Learner Objectives

Upon completion of this activity, you should be able to:

Evaluate emerging pharmacologic and device-based treatment options for uncontrolled and resistant hypertension.
Develop individualized, guideline-directed management strategies based on patient phenotype, comorbidities, and prior treatment response.

Program Committee and Faculty Disclosures

Planning Committee:
Dave Dixon, PharmD, BCACP, CLS, FACC
American College of Cardiology
Disclosure
Consultant Fees/Honoraria: Innovation Horizons

Eileen Handberg, PhD, ANRP, FACC
American College of Cardiology
Disclosure
Consulting Fees/Honoraria: Preventative Cardiovascular Nurses Association

Eugene Yang, MD, MS, FACC
American College of Cardiology
Disclosure
Consulting Fees/Honoraria: Idorsia, Kestra, Sky Labs

Faculty:

David De Padua Brasil, MD, FACC

American College of Cardiology

Disclosure

Speaker: Astra Zeneca (Brazil), LIBBS Faramaceutica Brasil, SERVIER (France and Brasil)

Voyager-PAD
Clinical Trial: Bayer Healthcare Pharmaceuticals

Eileen Handberg, PhD, ANRP, FACC
American College of Cardiology
Disclosure
Consulting Fees/Honoraria: Preventative Cardiovascular Nurses Association

Grant Acknowledgement
Educational grant support for this activity provided by AstraZeneca.

Summary

Availability:

On-Demand

Access expires on Oct 16, 2027

Cost:

FREE

Credit Offered:

0.75 CME Credit

0.75 CNE Credit

0.75 AAPA Credit

0.75 ABIM-MOC Point

0.75 IPCE Credit